This is a new and emerging CRISPR tool for gene therapy with few reports published so far, but given its potential in correcting the vast majority of mutations that cause Stargardt disease, including the most common STGD3 5 bp deletion in ELOVL4 [14], it is an incredibly exciting option for the future. The gene discussed is ELOVL4; the disease is Stargardt disease.